Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Cancer Discov. 2018 Sep 26;8(12):1529–1539. doi: 10.1158/2159-8290.CD-18-1022

Figure 3. Responses observed in the two patients treated with osimertinib and BLU-667.

Figure 3.

A. Treatment response of patient 1 to Osimertinib and BLU-667. Serial coronal contrast-enhanced computed-tomography images of the thorax demonstrate a right lower lobe lung mass and pleural nodularity (red arrows) seen at baseline (left) with partial response after 8 weeks of treatment with BLU-667 and osimertinib (right). B. Treatment response of patient 44 to osimertinib and BLU-667, with significant improvement in left upper and left lower lobe pulmonary opacities (right; circled) compared to baseline (left.)